ArticleScientific reports2026
Microinjection of CART peptide into the nucleus accumbens medial shell attenuates methamphetamine-induced anxiety-like behaviors via restoration of GABA
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Methamphetamine (METH) abuse often leads to anxiety-like behaviors, and the cocaine- and amphetamine-regulated transcript (CART) peptide, which is abundant in the nucleus accumbens (NAc), has shown promise in mitigating behavioral effects of psychostimulants. However, the role of CART peptide in the NAc medial shell in METH-induced anxiety remains poorly understood. In this study, following METH withdrawal and reinstatement, rats exhibited significant anxiety-like behaviors. Immunofluorescence analysis revealed a substantial increase in the proportion of c-Fos⁺/NeuN⁺ and CART⁺/NeuN⁺ cells within the NAc medial shell. Western blot and immunofluorescence consistently showed upregulated CART peptide expression and reduced gamma aminobutyric acid type B receptor (GABABR) levels in this region. Further immunofluorescence staining confirmed decreased GABABR expression specifically within CART-positive neurons. Microinjection of CART peptide into the NAc medial shell attenuated METH-induced anxiety-like behaviors, normalized the hyperactivity of neurons, and restored GABABR expression to baseline levels. Molecular docking and co-immunoprecipitation suggest a potential interaction between CART and GABABR. These protective effects were abolished by the GABABR antagonist CGP55845. Overall, our findings demonstrate that CART peptide delivery into the NAc medial shell alleviates METH-induced anxiety-like behaviors by rescuing GABABR membrane expression, highlighting a potential therapeutic pathway for METH-related anxiety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.